Healthcare / Medical DevicesNYSE American
$1.16
+0.07 (+6.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-6.3M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$45M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-136.6%
↓Gross Margin
65.7%
↑Debt/Equity
1.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
+49.4%
FCF CAGR
—
FCF margin
-43.6%
FCF / Net income
1.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $40.9M · net income $-15.6M · FCF $-17.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $40.9M | $40.9M | $32.6M | $19.2M | $15.6M | $13.9M | $7.6M | $3.8M | $2.4M | $1.6M | $1.1M |
| Net Income | $-15.6M | $-15.6M | $-6.2M | $-8.1M | $-10.7M | $-10.4M | $-11.6M | $-10.7M | $-10.3M | $-12.1M | $-3.6M |
| EBITDA | $-12.6M | $-12.6M | $-5.4M | $-7.7M | $-10.1M | — | — | — | — | — | — |
| EPS | -0.37 | -0.37 | -0.16 | -0.28 | -1.52 | -1.89 | — | — | — | — | — |
| Gross Margin | 65.7% | 65.7% | 71.2% | 68.5% | 65.9% | 74.4% | 65.7% | 63.0% | 70.2% | 67.6% | 74.4% |
| Operating Margin | -35.2% | -35.2% | -19.1% | -42.8% | -68.6% | -74.1% | -138.5% | -281.3% | -430.8% | -420.1% | -296.8% |
| Net Margin | -38.1% | -38.1% | -19.0% | -42.3% | -68.9% | -74.9% | -152.5% | -279.1% | -422.1% | -776.0% | -327.8% |
| Balance Sheet | |||||||||||
| Debt/Equity | 1.70 | 1.70 | 0.33 | 0.07 | 0.09 | — | — | 0.14 | — | — | — |
| Current Ratio | 2.73 | 2.73 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-17.8M | $-17.8M | $-4.7M | $-6.3M | $-10.3M | $-9.9M | $-9.1M | $-10.4M | $-9.7M | $-6.2M | $-3.2M |
| Returns | |||||||||||
| ROE | -136.6% | -136.6% | -25.0% | -90.6% | -168.6% | -67.3% | -100.0% | -166.7% | -160.5% | -97.2% | 20.6% |
| Valuation | |||||||||||
| P/B | 4.26 | 4.26 | 10.07 | 15.55 | 0.54 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | 25.7% | 25.7% | 69.2% | 23.7% | — | 82.7% | 97.6% | 57.0% | 56.8% | 41.3% | — |
| EPS Growth | -131.3% | -131.3% | 42.9% | 81.6% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-60.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → -0.37
Residual
-60.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.